Effect of valsartan on the incidence of diabetes and cardiovascular events.

Effect of valsartan on the incidence of diabetes and cardiovascular events.

BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients wit...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	McMurray, J, Holman, R, Haffner, S, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H
Format:	Journal article
Sprache:	English
Veröffentlicht:	2010

Ähnliche Einträge

Effect of nateglinide on the incidence of diabetes and cardiovascular events.
von: Holman, R, et al.
Veröffentlicht: (2010)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
von: Currie, G, et al.
Veröffentlicht: (2017)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
von: Califf, R, et al.
Veröffentlicht: (2008)

Effect of Valsartan on the Incidence of Diabetes REPLY
von: Holman, R, et al.
Veröffentlicht: (2010)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
von: Krum, H, et al.
Veröffentlicht: (2010)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
von: Bethel, M, et al.
Veröffentlicht: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
von: Bethel, M, et al.
Veröffentlicht: (2013)

Updated risk factors should be used to predict development of diabetes.
von: Bethel, M, et al.
Veröffentlicht: (2017)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
von: Mcmurray, J, et al.
Veröffentlicht: (2011)

High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test?
von: Bethel, M, et al.
Veröffentlicht: (2008)

The authors reply
von: Holman, R, et al.
Veröffentlicht: (2010)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
von: Latini, R, et al.
Veröffentlicht: (2013)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
von: Preiss, D, et al.
Veröffentlicht: (2013)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
von: Mcmurray, J, et al.
Veröffentlicht: (2012)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
von: McMurray, J, et al.
Veröffentlicht: (2012)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
von: Shen, L, et al.
Veröffentlicht: (2012)

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.
von: Bethel, M, et al.
Veröffentlicht: (2009)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
von: Shen, L, et al.
Veröffentlicht: (2013)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
von: Bethel, A, et al.
Veröffentlicht: (2005)

Determining the most appropriate components for a composite clinical trial outcome.
von: Bethel, M, et al.
Veröffentlicht: (2008)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
von: Holman, R, et al.
Veröffentlicht: (2003)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
von: Preiss, D, et al.
Veröffentlicht: (2012)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
von: Haynes, R, et al.
Veröffentlicht: (2018)

Prediabetes and the risk of diabetes.
von: McMurray, J, et al.
Veröffentlicht: (2012)

Phosphodiesterase 9 Inhibition Combined With Valsartan and With Sacubitril/Valsartan in Experimental Ovine Heart Failure
von: Nicola J. A. Scott, et al.
Veröffentlicht: (2024-12-01)

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration
von: Teo, K, et al.
Veröffentlicht: (2011)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
von: Kraus, W, et al.
Veröffentlicht: (2012)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
von: Sharma, A, et al.
Veröffentlicht: (2016)

Efficacy, Safety and Tolerability of Valsartan and Hydrochlorothiazide Compared to Valsartan and Amlodipine in Stage 2 Hypertension
von: Abdul karim, et al.
Veröffentlicht: (2022-06-01)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
von: McMurray, J, et al.
Veröffentlicht: (2004)

Sacubitril/Valsartan for heart failure
von: Wenqin Dai, MM, et al.
Veröffentlicht: (2022-06-01)

Impact of Solubility Enhancement Methods on the Dissolution Rate of Valsartan Sachet
von: Anjam H. Abdalla, et al.
Veröffentlicht: (2021-06-01)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
von: Huffman, K, et al.
Veröffentlicht: (2014)

Clinical pharmacology of angiotensin II receptor blockers: valsartan
von: M. V. Leonova
Veröffentlicht: (2014-12-01)

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups
von: Assaad-Khalil SH, et al.
Veröffentlicht: (2015-01-01)

Different chronotherapeutic effects of valsartan and olmesartan in non-dipper hypertensive patients during valsartan treatment at morning
von: Kentaro Ushijima, et al.
Veröffentlicht: (2015-01-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
von: Pei Yang, et al.
Veröffentlicht: (2022-08-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
von: Nor Hidayah Mustafa, et al.
Veröffentlicht: (2022-08-01)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
von: Yates, T, et al.
Veröffentlicht: (2014)

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.
von: Huffman, K, et al.
Veröffentlicht: (2014)